Navigation Links
Continuous Treatment With Abbott's HUMIRA(R) Achieves Superior Long-Term Efficacy for Psoriasis Patients Compared to Interrupting Treatment
Date:9/18/2008

Additional Analysis Shows HUMIRA Effectively Treats Adult Patients with

Moderate to Severe Psoriasis Regardless of Age, Duration of Disease,

Diagnosis of Psoriatic Arthritis or Recent Systemic Therapy

PARIS, Sept. 18 /PRNewswire-FirstCall/ -- More psoriasis patients achieve efficacy when they receive continuous treatment with HUMIRA(R) (adalimumab) compared to patients who interrupt their therapy, according to data presented at the European Academy of Dermatology and Venereology (EADV) Congress in Paris. The findings were from a sub-analysis of Abbott's pivotal, 52-week study, REVEAL (The Randomized Controlled EValuation of Adalimumab Every Other Week in Moderate to Severe Psoriasis Trial) and the period of open-label treatment that followed.

The sub-group analysis was designed to determine whether interrupting HUMIRA treatment would affect efficacy in psoriasis patients who had already achieved good response to HUMIRA. After 33 weeks, patients who had achieved adequate response to HUMIRA (as measured by PASI 75, or greater than 75 percent clearance) were randomized into two groups. One group continued to receive HUMIRA and the other was given placebo. Beginning at week 52, all patients received HUMIRA during the open-label extension period.

Patients who had maintained adequate response after HUMIRA was discontinued were more likely to achieve a PASI 75 response when they were restarted on treatment. Among those who discontinued and then re-started HUMIRA, 84 percent of the 161 patients who had maintained adequate response achieved PASI 75 after 24 weeks of re-treatment, compared to 55 percent of the 66 patients who had lost adequate response after stopping treatment. A loss of adequate response was defined as less than PASI 50 response relative to baseline and at least a 6-point increase in PASI score relative to week 33.

"The goal of treatment for dermatologists is to maintain disease remission, and these results ar
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
2. Echo Therapeutics Announces Publication of Positive Clinical Data for its Symphony Transdermal Continuous Glucose Monitoring System in Journal of Diabetes Science and Technology
3. Echo Therapeutics Initiates Clinical Study of Its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
4. Echo Therapeutics Announces Positive Results with the Prelude(TM) SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony(TM) Transdermal Continuous Glucose Monitoring System
5. EntreMed Commences Continuous Dosing Clinical Trial For MKC-1
6. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
7. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
8. AMT Obtains License to Amgens GDNF Gene to Develop Treatment for Parkinsons Disease with AMTs Proprietary Gene Therapy Platform
9. S*BIO Initiates U.S. Phase I Clinical Trials of Oral JAK2 Inhibitor SB1518 for the Treatment of Hematological Malignancies
10. Omeros and The Parkinsons Institute and Clinical Center Enter into a Collaboration Agreement to Evaluate Novel Target for the Treatment of Movement Disorders
11. Keraderm to Release $100 Phototherapy Treatment for Fungal Nail Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 /PRNewswire-iReach/ -- VAPETEK™, ... a vegetable-glycol solution for use in portable vaporizers, ... the active ingredients in cannabis, cannabidiol offers consumers ... vaporizer devices, and other vaporizer technology. ... Cannabis naturally contains 483 different compounds which are ...
(Date:7/11/2014)... , July 11, 2014 Patient ... marketing and, consequently, organizations are turning to an ... As part of this evolving approach ... to educate, communicate and engage patients throughout their ... to patient empowerment. By mapping the patient journey ...
(Date:7/11/2014)... July 11, 2014 The consumer marketing ... across industry sectors to better identify winning tools ... to engage with and understand consumers, as new ... make critical purchasing decisions. According ... LLC, one area where organizations can observe a ...
Breaking Medicine Technology:VAPETEK Releases CBD-Infused eLiquid For The Consumer Market 2New Study Uses Six-Step Patient Journey as Framework for Consumer-Focused Marketing Opportunities 2New Technologies Transforming Consumer Marketing Research Playbook 2
... , SOUTH SAN FRANCISCO, Calif., July 8 Rigel Pharmaceuticals, ... Company plans to host a conference call on Thursday, July ... Members of Rigel,s senior management team and the principal investigator ... 2b TASKi2 clinical trial of R788 in rheumatoid arthritis, the ...
... OAKS, Calif., July 7 Amgen (Nasdaq: ... head-to-head trial evaluating denosumab versus Zometa(R) (zoledronic acid) in ... advanced breast cancer met its primary and secondary endpoints ... was demonstrated for both delaying the time to the ...
Cached Medicine Technology:Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi2 Clinical Trial of R788 in Rheumatoid Arthritis 2Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 2Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 3Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 4Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 5Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 6Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 7Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 8
(Date:7/12/2014)... 12, 2014 Utah Valley Entrepreneurial Forum ... with awards being bestowed to companies in revenue, and ... entrepreneur community with recognition for new ideas as well ... incoming revenue. , 25 Under 5 highlights outstanding Utah ... are under 5 years old. Award recipients were recognized ...
(Date:7/12/2014)... Restore My Vision Today is a new ... couple boasting very impressive credentials on the field of ... as a way to help consumers do without the ... respective patients’ treatments . , In particular, ... of pertinent information relevant to eye care like:, ...
(Date:7/11/2014)... July 12, 2014 Recently, MagicQuinceaneraDresses.com, the ... its new collection of 2014 Quinceanera dresses . ... who want to look fashionable without paying a large ... prices, up to 57% off. , The company’s online ... to get amazing special occasion outfits. In addition to ...
(Date:7/11/2014)... 2014 As transvaginal mesh lawsuits ... & Johnson’s Ethicon Inc. unit continue to mount ... the Texas Attorney General’s Office has acknowledged that ... mesh products used to treat pelvic organ prolapse ... from kens5.com, the probe began nearly two years ...
(Date:7/11/2014)... July 11, 2014 Volunteers from ... drug abuse this week with drug education lectures, forums ... booklet distribution in cities around the world. , Drug ... National Institute on Drug Abuse, abuse of alcohol and ... in crime, lost work, decreased productivity and healthcare. ...
Breaking Medicine News(10 mins):Health News:SquareHook is Recognized for UVEF 25 Businesses Under 5 Years-Watch Out 2Health News:Restore My Vision Today | Groundbreaking Book Reveals How To Restore Your Vision Without The Use of Glasses – Vinamy 2Health News:Restore My Vision Today | Groundbreaking Book Reveals How To Restore Your Vision Without The Use of Glasses – Vinamy 3Health News:Cheap Quinceanera Dresses Now Available At MagicQuinceaneraDresses.com 2Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 2Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 3Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 4Health News:Scientologists Taking Action against Drug Abuse 2Health News:Scientologists Taking Action against Drug Abuse 3
... and whether teens smoke , MONDAY, March 15 (HealthDay ... proclaimed to women, "You,ve come a long way, baby!" ... war on cigarette advertising that targets teens, especially teenage ... Although the 1998 settlement agreement between big tobacco and ...
... ... wrestles with their own Trillion Dollar Question: How do we increase employee productivity ... Inc. the maker of Sweat365.com, unveils “The Healthy Corp” a breakthrough product that ... ...
... March 15 To better understand and ... programs, the Midwest Business Group on Health ... employers, health management programs. The non-profit coalition of more ... results indicating that 72% of doctors surveyed agree that ...
... Food and Chemical Sensitivity , announced that Philip Voluck has joined the firm and is establishing a new company that will be known as PreviMedica Lifestyle Medicine ... ... ... ...
... ... ... ... WHITE PLAINS, N.Y. , March 15 Mission Pharmacal announced today that it will partner with the March of Dimes to distribute ...
... In an economy that seems stuck on stagnate, business is booming, thank you, for LTC Financial Partners LLC (LTCFP), one of ... firm seeks to expand its army of agents by 300 this year, an increase of about 60% over last year. , ... ... , ...
Cached Medicine News:Health News:Teen Girls Say Pink Camel in Cigarette Ads Caught Their Eye 2Health News:Teen Girls Say Pink Camel in Cigarette Ads Caught Their Eye 3Health News:Konamoxt, Inc. Redefines Corporate Wellness with The Healthy Corp, a Customizable Corporate Wellness Platform 2Health News:Konamoxt, Inc. Redefines Corporate Wellness with The Healthy Corp, a Customizable Corporate Wellness Platform 3Health News:Doctors Support Efforts of Employers and Health Plans to Improve Health of Patients 2Health News:Doctors Support Efforts of Employers and Health Plans to Improve Health of Patients 3Health News:Doctors Support Efforts of Employers and Health Plans to Improve Health of Patients 4Health News:Doctors Support Efforts of Employers and Health Plans to Improve Health of Patients 5Health News:Cell Science Systems Recruits Seasoned Executive to Head New Lifestyle Medicine & Nutritional Solution for Health Care Professionals 2Health News:Cell Science Systems Recruits Seasoned Executive to Head New Lifestyle Medicine & Nutritional Solution for Health Care Professionals 3Health News:Cell Science Systems Recruits Seasoned Executive to Head New Lifestyle Medicine & Nutritional Solution for Health Care Professionals 4Health News:Mission Pharmacal and March of Dimes Share Commitment to Healthy Babies 2Health News:Mission Pharmacal and March of Dimes Share Commitment to Healthy Babies 3Health News:Mission Pharmacal and March of Dimes Share Commitment to Healthy Babies 4Health News:Long Term Care Insurance Leader Seeks 320 New Agents in 2010, Following Strong 2009 Growth 2Health News:Long Term Care Insurance Leader Seeks 320 New Agents in 2010, Following Strong 2009 Growth 3Health News:Long Term Care Insurance Leader Seeks 320 New Agents in 2010, Following Strong 2009 Growth 4
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
... The Wet-Field Coagulator provides precise episcleral, ... peripheral tissue trauma. Controlled Rf diathermy ... comprehensive line of bipolar Eraser instruments, ... enhanced features that ensure a high ...
Medicine Products: